Hyperfine reported first-quarter revenue of $3.9 million, up 83% year over year, driven by adoption of its next-generation Swoop portable MRI system. The company sold 10 units in the quarter, with most being next-generation systems. Gross margin expanded to 50.7% from 41.3%, whilst net loss narrowed to $8.6 million. Hyperfine ended the quarter with $40.8 million in cash, supported by an initial $15 million debt tranche. The company reiterated full-year 2026 guidance for revenue of $20 million to $22 million and gross margin of 50% to 55%. Management highlighted pipeline strength in hospitals, neurology offices and international markets, plus progress towards a potential FDA submission for contrast-enhanced MRI use by end-2026.

Hyperfine Inc reported an 83% year-over-year revenue increase to $3.9 million for Q1 2026, with gross margins reaching 51% for the third consecutive quarter above 50%. The medical imaging company achieved CE and UKCA marks for its next-generation subsystem and advanced DWI Optiv AI software, enabling international expansion. Despite revenue growth, Hyperfine posted a net loss of $8.6 million and burnt through $8.8 million in cash during the quarter. The company maintains a cash position of $40.8 million, providing runway into 2028. Hyperfine's contrast PMR study enrollment has surpassed 50% of its target, supporting a potential FDA submission by end-2026. The company is focusing on larger medical offices and integrated delivery networks for its second-generation system deployments.

Hyperfine has introduced its Swoop portable MRI system at the All India Institute of Medical Sciences (AIIMS) in New Delhi, marking India's first deployment of bedside brain imaging technology for routine clinical use. The FDA-cleared, AI-powered system is now performing brain scans under Dr Shailesh Gaikwad's leadership at AIIMS's Centre for Neurological Conditions. The Swoop system addresses critical gaps in India's healthcare infrastructure by bringing MRI directly to patients' bedsides without requiring dedicated rooms, specialised power or patient transport. It supports neurological care across stroke units, trauma centres, intensive care units and neonatal wards. Radiosurgery Global serves as the exclusive distributor in India. The deployment establishes a foundation for clinical research, with AIIMS New Delhi positioned to generate real-world evidence for point-of-care brain imaging adoption across the country.